IFM Therapeutics

Overview

IFM Therapeutics is a biotechnology company dedicated to developing next-generation small molecule therapies targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and related innate immune pathways. Founded in 2015, the company has established itself as a leader in NLRP3 biology and drug discovery, with a particular focus on inflammatory and neurodegenerative diseases.

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2015 |
| Headquarters | Boston, Massachusetts, USA |
| CEO | Dr. Gregory Licholai |
| Parent | Subsidiary of Bristol-Myers Squibb (acquired 2020) |
| Focus | NLRP3 and innate immunity modulators |
| Stage | Preclinical/Phase 1 |

History and Corporate Structure

IFM Therapeutics was founded by Dr. Gregory Licholai and a team of scientists from Harvard Medical School and Massachusetts General Hospital. The company's founding was based on pioneering research in NLRP3 biology and its role in inflammatory diseases.

In 2020, Bristol-Myers Squibb (BMS) acquired IFM Therapeutics, making it a wholly-owned subsidiary. The acquisition gave BMS access to IFM's NLRP3 pipeline and expertise in innate immunity drug discovery. The company operates as an independent unit within BMS, focusing on NLRP3-related programs for oncology and inflammation.

Science and Technology

NLRP3 Platform

IFM's platform is built on deep expertise in NLRP3 biology:

Overview

IFM Therapeutics is a biotechnology company dedicated to developing next-generation small molecule therapies targeting the [NLRP3 inflammasome](/entities/nlrp3-inflammasome) and related innate immune pathways. Founded in 2015, the company has established itself as a leader in NLRP3 biology and drug discovery, with a particular focus on inflammatory and neurodegenerative diseases.

Company Profile

| Attribute | Value |
|-----------|-------|
| Founded | 2015 |
| Headquarters | Boston, Massachusetts, USA |
| CEO | Dr. Gregory Licholai |
| Parent | Subsidiary of Bristol-Myers Squibb (acquired 2020) |
| Focus | NLRP3 and innate immunity modulators |
| Stage | Preclinical/Phase 1 |

History and Corporate Structure

IFM Therapeutics was founded by Dr. Gregory Licholai and a team of scientists from Harvard Medical School and Massachusetts General Hospital. The company's founding was based on pioneering research in NLRP3 biology and its role in inflammatory diseases.

In 2020, Bristol-Myers Squibb (BMS) acquired IFM Therapeutics, making it a wholly-owned subsidiary. The acquisition gave BMS access to IFM's NLRP3 pipeline and expertise in innate immunity drug discovery. The company operates as an independent unit within BMS, focusing on NLRP3-related programs for oncology and inflammation.

Science and Technology

NLRP3 Platform

IFM's platform is built on deep expertise in NLRP3 biology:

• Structural biology: Understanding of NLRP3 NACHT domain and inhibition sites
• Medicinal chemistry: Optimized small molecules for potency and selectivity
• Biomarkers: Development of patient selection biomarkers

Pipeline Overview

| Program | Mechanism | Indication | Stage | Status |
|---------|-----------|------------|-------|--------|
| IFM-2427 | NLRP3 inhibitor | Inflammatory diseases | Preclinical | IND-enabling |
| IFM-3547 | NLRP3/BTK dual | Neurodegeneration | Discovery | Lead optimization |
| IFM-3029 | NLRP3 degrader | Cancer | Discovery | Early stage |

Neurodegeneration Programs

Parkinson's Disease

IFM is developing NLRP3 inhibitors specifically for Parkinson's disease:

• Target: Neuroinflammation driven by NLRP3 activation in microglia
• Approach: Brain-penetrant small molecules that inhibit NLRP3 oligomerization
• Rationale: Postmortem studies show increased NLRP3 and ASC specks in PD substantia nigra

Alzheimer's Disease

The company also has programs targeting Alzheimer's disease:

• Mechanism: Blockade of Aβ-induced NLRP3 activation in microglia
• Combination potential: Synergy with anti-amyloid antibodies

Academic Collaborations

IFM has established collaborations with leading academic centers:

• Massachusetts General Hospital: Dr. Marco Colonna - NLRP3 biology
• University of Pennsylvania: Dr. Virginia Woolf - Inflammasome signaling
• University of Pittsburgh: Dr. M. K. Jones - Microglial activation

Clinical Development Strategy

IFM's approach to clinical development includes:

Competitive Position

| Company | Strength | Weakness |
|---------|----------|----------|
| IFM (BMS) | Big pharma resources, deep biology | Less CNS-specific focus |
| NodThera | Dedicated CNS, Phase 1 data | Smaller company |
| Olacteant | Clinical data, oral delivery | Limited CNS penetration |
| Novartis | Resources, DFV890 | Broader focus |

Pipeline Development Timeline

gantt
title IFM Therapeutics NLRP3 Development
dateFormat YYYY
axisFormat %Y

section IFM-2427
Discovery :done, 2020, 2022
Preclinical :active, 2022, 2024
IND-enabling :2024, 2025
Phase 1 :2025, 2026

section IFM-3547
Lead optimization :active, 2023, 2025
Preclinical :2025, 2026
IND filing :2026, 2027

References

See Also

• [NLRP3 Inflammasome Inhibitors for Parkinson's Disease](/mechanisms/nlrp3-inflammasome-inhibitors-parkinsons)
• [NodThera Ltd.](/companies/nodthera)
• [Bristol-Myers Squibb](/companies/bristol-myers-squibb)
• [NLRP3 Inhibitors Investment Landscape](/investment/nlrp3-inflammasome)